Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced upcoming investor conference presentations. CEO Dr. Adi Mor will deliver corporate presentations at two events:
1. H.C. Wainwright 26th Annual Global Investment Conference: A prerecorded webcast available from September 9, 2024, at 7:00 am ET for 90 days.
2. HBM Biopharma Summit 2024 in Zurich, Switzerland: A live in-person presentation scheduled for September 23, 2024, at 10:45 am CET at the Park Hyatt Zurich.
The H.C. Wainwright presentation will be accessible via webcast, while the HBM Summit presentation will not be webcast. These presentations offer investors insights into Chemomab's innovative therapeutics for high unmet need fibro-inflammatory diseases.
Chemomab Therapeutics (Nasdaq: CMMB), una società biotecnologica in fase clinica focalizzata sulle malattie fibro-infiammatorie, ha annunciato prossime presentazioni per investitori. Il CEO Dr. Adi Mor terrà presentazioni aziendali a due eventi:
1. H.C. Wainwright 26th Annual Global Investment Conference: Una web conference preregistrata disponibile dal 9 settembre 2024, alle 7:00 ora ET per 90 giorni.
2. HBM Biopharma Summit 2024 a Zurigo, Svizzera: Una presentazione dal vivo programmata per il 23 settembre 2024, alle 10:45 ora CET presso il Park Hyatt di Zurigo.
La presentazione di H.C. Wainwright sarà accessibile via webcast, mentre la presentazione del Summit HBM non sarà trasmessa. Queste presentazioni offrono agli investitori informazioni sulle innovative terapie di Chemomab per malattie fibro-infiammatorie ad alto bisogno insoddisfatto.
Chemomab Therapeutics (Nasdaq: CMMB), una empresa de biotecnología en etapa clínica centrada en enfermedades fibro-inflamatorias, ha anunciado próximas presentaciones en conferencias para inversores. El CEO Dr. Adi Mor realizará presentaciones corporativas en dos eventos:
1. H.C. Wainwright 26th Annual Global Investment Conference: Una transmisión web grabada disponible a partir del 9 de septiembre de 2024, a las 7:00 am ET durante 90 días.
2. HBM Biopharma Summit 2024 en Zúrich, Suiza: Una presentación en persona programada para el 23 de septiembre de 2024, a las 10:45 am CET en el Park Hyatt Zúrich.
La presentación de H.C. Wainwright estará disponible a través de una transmisión web, mientras que la presentación del Summit HBM no será transmitida. Estas presentaciones brindan a los inversores información sobre las terapias innovadoras de Chemomab para enfermedades fibro-inflamatorias con una alta necesidad no satisfecha.
Chemomab Therapeutics (Nasdaq: CMMB), 섬유 염증 질환에 중점을 둔 임상 단계의 생명공학 회사가 다가오는 투자자 회의 발표를 발표했습니다. CEO Dr. Adi Mor가 두 개의 이벤트에서 기업 발표를 진행합니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의: 2024년 9월 9일 오전 7시 ET부터 90일 동안 이용 가능한 사전 녹화된 웹캐스트.
2. 2024 HBM 바이오제약 정상 회담 스위스 취리히: 2024년 9월 23일 오전 10시 45분 CET에 Park Hyatt Zurich에서 예정된 라이브 대면 발표.
H.C. Wainwright의 발표는 웹캐스트를 통해 이용 가능하며, HBM 서밋 발표는 웹캐스트되지 않습니다. 이러한 발표는 투자자들에게 Chemomab의 높은 미충족 요구에 대한 혁신적인 치료법에 대한 통찰력을 제공합니다.
Chemomab Therapeutics (Nasdaq: CMMB), une entreprise de biotechnologie en phase clinique axée sur les maladies fibro-inflammatoires, a annoncé des présentations à venir lors de conférences pour investisseurs. Le PDG Dr. Adi Mor fera des présentations d'entreprise lors de deux événements :
1. H.C. Wainwright 26th Annual Global Investment Conference : Un webinaire préenregistré disponible à partir du 9 septembre 2024, à 7h00 ET pendant 90 jours.
2. HBM Biopharma Summit 2024 à Zurich, en Suisse : Une présentation en direct prévue pour le 23 septembre 2024, à 10h45 CET au Park Hyatt de Zurich.
La présentation de H.C. Wainwright sera accessible par webinaire, tandis que celle du sommet HBM ne sera pas diffusée. Ces présentations offrent aux investisseurs un aperçu des thérapies innovantes de Chemomab pour des maladies fibro-inflammatoires à fort besoin non satisfait.
Chemomab Therapeutics (Nasdaq: CMMB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf fibro-inflammatorische Erkrankungen konzentriert, hat bevorstehende Präsentationen für Investoren angekündigt. CEO Dr. Adi Mor wird auf zwei Veranstaltungen Unternehmenspräsentationen halten:
1. H.C. Wainwright 26th Annual Global Investment Conference: Eine aufgezeichnete Webcast-Präsentation, die ab 9. September 2024 um 7:00 Uhr ET für 90 Tage verfügbar ist.
2. HBM Biopharma Summit 2024 in Zürich, Schweiz: Eine persönliche Live-Präsentation, die für 23. September 2024 um 10:45 Uhr CET im Park Hyatt Zürich geplant ist.
Die H.C. Wainwright-Präsentation wird über einen Webcast zugänglich sein, während die Präsentation des HBM-Sommits nicht über Webcast verfügbar sein wird. Diese Präsentationen bieten Investoren Einblicke in Chemomabs innovative Therapien für fibro-inflammatorische Erkrankungen mit einem hohen unbefriedigten Bedarf.
- None.
- None.
TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver corporate presentations at the H.C. Wainwright 26th Annual Global Investment Conference and at the HBM Biopharma Summit 2024 in Zurich, Switzerland. Dr. Mor’s prerecorded H.C. Wainwright presentation will be webcast and is available starting on September 9, 2024 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website. Dr. Mor’s live presentation at the HBM Biopharma Summit is scheduled at 10:45 am CET on September 23, 2024. Company presentations at the HBM Summit will not be webcast.
| Chemomab Presentation at 2024 H.C. Wainwright 26th Annual Global Investment Conference | |
Date: Time: Venue: Format: Webcast Link: | September 9, 2024 Available starting at 7:00 am ET for 90 days Virtual Prerecorded webcast presentation https://journey.ct.events/view/62306e1b-1dae-4bbf-b114-6eaff1f09ae8 |
| Chemomab Presentation at HBM Biopharma Summit 2024 | |
Date: Time: Venue: Format: Information: | September 23, 2024 10:45 am CET Park Hyatt Zurich Live in person presentation https://hbmbiopharmasummit2024.events.hbmpartners.com/ |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated to date, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients, including a Phase 2 trial in patients with primary sclerosing cholangitis (PSC), a Phase 2a liver fibrosis trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), a Phase 1b study in patients with metabolic dysfunction–associated fatty liver disease (MAFLD) and an investigator-initiated study in patients with severe lung injury. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When and where will Chemomab Therapeutics (CMMB) present at the H.C. Wainwright Conference in September 2024?
What is the date and time of Chemomab's (CMMB) presentation at the HBM Biopharma Summit 2024?
Who will be presenting on behalf of Chemomab Therapeutics (CMMB) at the September 2024 investor conferences?
Will the Chemomab (CMMB) presentation at the HBM Biopharma Summit 2024 be webcast?
